Shanghai Yizhong Pharmaceutical Co Ltd (688091) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.014x

Based on the latest financial reports, Shanghai Yizhong Pharmaceutical Co Ltd (688091) has a cash flow conversion efficiency ratio of 0.014x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥21.03 Million ≈ $3.08 Million USD) by net assets (CN¥1.46 Billion ≈ $213.78 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Shanghai Yizhong Pharmaceutical Co Ltd for the company's overall valuation and market capitalisation.

Shanghai Yizhong Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2017–2024)

This chart illustrates how Shanghai Yizhong Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Shanghai Yizhong Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Shanghai Yizhong Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency. Explore 688091 cash to earnings ratio to measure how well operating cash flow supports reported net income.

Company	Cash Flow Conversion Efficiency
Med Life SA RO:M	0.146x
Jiangling Motors Corp Ltd SHE:000550	0.015x
Chengdu Leejun Industrial Co Ltd SHE:002651	0.000x
Gemadept Corp VN:GMD	0.103x
Anhui Guofeng Plastic Industry Co Ltd SHE:000859	-0.005x
Suzhou Huaya Intelligence Technology Co Ltd SHE:003043	0.014x
Nabors Industries Ltd F:NBI1	0.079x
Landis+Gyr Group AG SW:LAND	0.066x

Annual Cash Flow Conversion Efficiency for Shanghai Yizhong Pharmaceutical Co Ltd (2017–2024)

The table below shows the annual cash flow conversion efficiency of Shanghai Yizhong Pharmaceutical Co Ltd from 2017 to 2024. View 688091 live share price for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	CN¥1.41 Billion ≈ $205.60 Million	CN¥39.44 Million ≈ $5.77 Million	0.028x	-52.50%
2023-12-31	CN¥1.46 Billion ≈ $214.35 Million	CN¥86.55 Million ≈ $12.67 Million	0.059x	-29.64%
2022-12-31	CN¥1.32 Billion ≈ $193.04 Million	CN¥110.78 Million ≈ $16.21 Million	0.084x	+302.36%
2021-12-31	CN¥1.18 Billion ≈ $172.02 Million	CN¥-48.78 Million ≈ $-7.14 Million	-0.041x	+50.00%
2020-12-31	CN¥243.51 Million ≈ $35.63 Million	CN¥-20.21 Million ≈ $-2.96 Million	-0.083x	+7.88%
2019-12-31	CN¥265.35 Million ≈ $38.83 Million	CN¥-23.91 Million ≈ $-3.50 Million	-0.090x	-78.92%
2018-12-31	CN¥212.18 Million ≈ $31.05 Million	CN¥-10.68 Million ≈ $-1.56 Million	-0.050x	+13.58%
2017-12-31	CN¥197.57 Million ≈ $28.91 Million	CN¥-11.51 Million ≈ $-1.68 Million	-0.058x	--

About Shanghai Yizhong Pharmaceutical Co Ltd

SHG:688091 China Drug Manufacturers - Specialty & Generic

Market Cap

$1.25 Billion

CN¥8.56 Billion CNY

Market Cap Rank

#8013 Global

#1848 in China

Share Price

CN¥41.41

Change (1 day)

-0.58%

52-Week Range

CN¥35.74 - CN¥64.82

All Time High

CN¥95.97